전장 유전체 및 엑솜 시퀀싱 시장 : 용도별, 생물종별, 제품별, 전장 유전체/엑솜별 - 경영진 및 컨설턴트용 가이드 포함, 소비자용 직접 검사(DTC) 분석 - 제7판(2026-2030년)

Report Overview:

Whole Genome Sequencing (WGS) refers to a genomic testing approach that determines the complete DNA sequence of an organism's genome at a single point in time. In humans, WGS analyzes approximately three billion base pairs, providing comprehensive information about genetic variation across both coding and non-coding regions of the genome. Unlike targeted sequencing methods that focus on specific genes or genomic regions, WGS provides an unbiased view of genetic variation, enabling identification of single nucleotide variants, insertions and deletions, copy number variations, structural variants, and other genomic alterations.

The Whole Genome Sequencing market has expanded significantly over the past decade as advances in next-generation sequencing (NGS) technologies have reduced the cost and time required to sequence human genomes. The global WGS market is currently estimated to be USD 2.84 billion annually and is expected to grow at compound annual growth rates of 21.1% over to 2030, reaching 7.4 Billion.

Growth in the WGS market is closely linked to increasing adoption of precision medicine, expanding clinical applications of genomic testing, and growing use of genomic data in pharmaceutical research and drug development. WGS is increasingly used in oncology, rare disease diagnosis, reproductive health testing, infectious disease surveillance, and population genomics initiatives.

Technology Overview

Whole genome sequencing is typically performed using next-generation sequencing platforms capable of processing millions to billions of DNA fragments in parallel. Sequencing workflows generally include DNA extraction, library preparation, sequencing reactions, and bioinformatics analysis.

Short-read sequencing technologies currently represent the most widely used approach due to high accuracy and relatively low cost per base. These technologies generate large numbers of short DNA sequence reads that are computationally assembled to reconstruct the genome.

Long-read sequencing technologies are emerging as complementary approaches that enable improved detection of structural genomic variations and repetitive sequences. Long-read technologies may provide improved characterization of genomic regions that are difficult to analyze using short-read methods.

Advances in sequencing chemistry, automation, and bioinformatics have improved throughput and reduced sequencing costs. Automation of library preparation workflows has improved reproducibility and reduced labor requirements.

Cloud-based bioinformatics tools are increasingly used to manage large genomic datasets and support interpretation of sequencing results.

Clinical Applications

Whole genome sequencing is used across a wide range of clinical applications. In oncology, WGS can identify genetic mutations associated with tumor development and progression. Comprehensive genomic profiling may identify actionable mutations that guide selection of targeted therapies.

Rare disease diagnosis represents another important application area. Many rare diseases have genetic origins, and WGS can help identify pathogenic variants responsible for disease symptoms, particularly in cases where previous diagnostic tests have failed to identify a cause.

Reproductive health applications include carrier screening and preimplantation genetic testing, where genomic information is used to assess risk of inherited disorders.

Pharmacogenomics applications use genomic information to predict patient response to medications and guide dosing decisions.

Infectious disease surveillance uses genomic sequencing to monitor pathogen evolution and identify emerging variants.

Population genomics initiatives involve sequencing large numbers of individuals to support research into genetic contributions to disease risk.

Market Drivers

Several factors are driving growth in the WGS market.

Declining sequencing costs are increasing accessibility of genomic testing for both research and clinical applications.

Increasing adoption of precision medicine approaches is creating demand for comprehensive genomic data to guide treatment decisions.

Growing use of genomic data in pharmaceutical research is supporting drug target identification and biomarker discovery.

Government-funded population genomics initiatives are generating demand for large-scale sequencing projects.

Advances in bioinformatics tools are improving interpretation of genomic data and supporting clinical adoption.

Increasing awareness of genetic testing among healthcare providers and patients is supporting demand growth.

Expansion of genomic databases is improving understanding of gene-disease relationships.

Market Segmentation

The WGS market can be segmented by product type, application, end user, and geographic region.

By product type, sequencing instruments represent an important segment, while consumables such as sequencing reagents represent a significant portion of recurring revenue. Bioinformatics software and sequencing services also represent important segments.

By application, oncology represents one of the largest segments due to importance of genomic profiling in cancer treatment. Rare disease diagnostics and reproductive health testing also represent significant application areas.

End users include academic research institutions, hospital laboratories, pharmaceutical companies, biotechnology companies, and contract research organizations.

North America represents the largest geographic market due to strong genomics research infrastructure and adoption of precision medicine technologies. Europe and Asia-Pacific markets are also expanding as investment in genomic research increases.

Competitive Landscape

The WGS market includes sequencing platform manufacturers, reagent suppliers, sequencing service providers, and bioinformatics companies.

Competition is driven by improvements in sequencing accuracy, throughput, cost efficiency, and data analysis capabilities.

Companies are increasingly offering integrated solutions combining sequencing instruments, consumables, and bioinformatics tools.

Strategic partnerships between sequencing technology providers and pharmaceutical companies are common, particularly in biomarker discovery and clinical trial applications.

Access to large genomic datasets is becoming an important competitive differentiator.

Barriers to entry remain significant due to capital requirements and intellectual property considerations.

Future Outlook

The WGS market is expected to continue expanding as sequencing technologies become more widely integrated into healthcare systems and research programs.

Declining sequencing costs may support broader adoption of whole genome sequencing in routine clinical practice.

Advances in artificial intelligence and bioinformatics tools are expected to improve interpretation of genomic data.

Long-read sequencing technologies may improve detection of structural variants and complex genomic regions.

Population genomics initiatives may increase use of genomic data in preventive medicine.

Integration of genomic data into electronic health records may support personalized treatment approaches.

Overall, whole genome sequencing represents a foundational technology supporting precision medicine, biomedical research, and drug development. Continued technological innovation and expanding clinical applications are expected to support sustained market growth.

Table of Contents

1 Market Guides

• 1.1 Whole Genome Sequencing Market - Strategic Situation Analysis
  • 1.1.1 Strategic Importance in Precision Medicine
  • 1.1.2 Cost Reduction and Economic Value Challenges
  • 1.1.3 Data Interpretation and Bioinformatics Bottlenecks
  • 1.1.4 Technology Innovation and Platform Competition
  • 1.1.5 Regulatory and Ethical Considerations
  • 1.1.6 Clinical Adoption and Workflow Integration
  • 1.1.7 Dependence on Pharmaceutical and Research Markets
  • 1.1.8 Competitive Landscape and Industry Structure
  • 1.1.9 Geographic Market Dynamics
  • 1.1.10 Outlook and Strategic Implications
• 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
• 1.3 Guide for Management Consultants and Investment Advisors
• 1.4 Impact of Artificial Intelligence on WGS

2 Introduction and Market Definition

• 2.1 Whole Genome Sequencing Definition In This Report
  • 2.1.1 Whole and Exome Sequencing
  • 2.1.2 Research
  • 2.1.3 Clinical Human
  • 2.1.4 Clinical Human Rapid
  • 2.1.5 Clinical Tumor
  • 2.1.6 Clinical Pathogen
  • 2.1.7 Agri/Other
  • 2.1.8 Direct to Consumer
• 2.2 The Genomics Revolution
• 2.3 Market Definition
  • 2.3.1 Revenue Market Size
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 Perspective: Healthcare and the IVD Industry
  • 2.5.1 Global Healthcare Spending
  • 2.5.2 Spending on Diagnostics
  • 2.5.3 Important Role of Insurance for Diagnostics
• 2.6 Sizing the Genome - Not What You Think
  • 2.6.1 Cost, Price and Genome Size, Pricing Practice
• 2.7 GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3 Market Overview

• 3.1 Market Participants Play Different Roles
  • 3.1.1 Instrument Manufacturer
  • 3.1.2 Independent lab specialized/esoteric
  • 3.1.3 Independent lab national/regional
  • 3.1.4 Independent lab analytical
  • 3.1.5 Public National/regional lab
  • 3.1.6 Hospital lab
  • 3.1.7 Physician lab
  • 3.1.8 DTC Lab
  • 3.1.9 Sequencing Labs
  • 3.1.10 Audit body
• 3.2 Whole Genome Sequencing - Markets, Examples and Discussion
  • 3.2.1 Direct to Consumer - Two Approaches
    • 3.2.1.1 The New Age of Medical Information
    • 3.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
    • 3.2.1.3 Newborn and Prenatal - A Brave New World
    • 3.2.1.4 DTC - How Many Segments?
  • 3.2.2 Research Markets
    • 3.2.2.1 Research Funding and Capital Expense
    • 3.2.2.2 WGS Datasets Preferred
    • 3.2.2.3 Existing research repurposed
    • 3.2.2.4 Organism Wide Market
    • 3.2.2.5 Service Suppliers Respond
  • 3.2.3 Clinical - Understanding Germline and Somatic
    • 3.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
  • 3.2.4 Pathogen Testing
    • 3.2.4.1 The Hepatitis C Story
    • 3.2.4.2 Will the Microbiology Department Disappear?
  • 3.2.5 AgriBio - Big Business
    • 3.2.5.1 GMO is Here to Stay
    • 3.2.5.2 WGS Benefits and Risks
    • 3.2.5.3 The New Agriculture
• 3.3 Industry Structure
  • 3.3.1 Hospital's Testing Share
  • 3.3.2 Economies of Scale
  • 3.3.3 Instrument Manufacturer Role
  • 3.3.4 Healthcare Industry Impacts - Still Struggling
    • 3.3.4.1 Can the Healthcare Industry Adapt?
    • 3.3.4.2 Genetic Counselling as an Industry
    • 3.3.4.3 WGES Adoption and Cannibalization
    • 3.3.4.4 The Meaning of Grail

4 Market Trends

• 4.1 Factors Driving Growth
  • 4.1.1 Diagnostic Factors
  • 4.1.2 Interpreting the Code Otherwise
  • 4.1.3 Changes in Agriculture
  • 4.1.4 Fertility Technology Comes of Age
  • 4.1.5 Pathogen Challenges
• 4.2 Factors Limiting Growth
  • 4.2.1 Increased Competition Lowers Price
  • 4.2.2 Lower Costs
  • 4.2.3 Healthcare Cost Concerns Curtail Growth
  • 4.2.4 Wellness has a downside
  • 4.2.5 GMO Opposition Movement
• 4.3 Sequencing Instrumentation
  • 4.3.1 Instrumentation Tenacity
  • 4.3.2 Declining Cost Changes Industry Structure
  • 4.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
  • 4.3.4 Illumina
  • 4.3.5 ION
  • 4.3.6 Pacific Biosystems
  • 4.3.7 Roche 454
  • 4.3.8 SOLiD
  • 4.3.9 Oxford Nanopore
    • 4.3.9.1 What is Oxford Nanopore Sequencing?
    • 4.3.9.2 What can Oxford Nanopore Sequencingt be used for?
    • 4.3.9.3 Oxford Nanopore Products
  • 4.3.10 Long Reads - Further Segmentation
  • 4.3.11 Linked Reads
  • 4.3.12 Targeted Sequencing Adopts CRISPR
  • 4.3.13 New Sequencing Technologies
    • 4.3.13.1 RNAP sequencing
    • 4.3.13.2 In vitro virus high-throughput sequencing
    • 4.3.13.3 Tunnelling currents DNA sequencing
    • 4.3.13.4 Sequencing by hybridization
    • 4.3.13.5 Sequencing with mass spectrometry
    • 4.3.13.6 Microfluidic Sanger sequencing
    • 4.3.13.7 Microscopy-based techniques

5 WGES Recent Developments

• 5.1 Recent Developments - Importance and How to Use This Section
  • 5.1.1 Importance of These Developments
  • 5.1.2 How to Use This Section
• 5.2 GeneDx to Acquire Fabric Genomics
• 5.3 WGS provides faster detection of Salmonella
• 5.4 UltraRapid WGS, Results in 48 Hours
• 5.5 WGS Identifies Desirable Tobacco Genes
• 5.6 The Case for WGS use in All Blood Cancers
• 5.7 $400 Personal WGS
• 5.8 Incorporating WGS into Cancer Care
• 5.9 Epic, GeneDx to broaden WGS potential
• 5.10 Qiagen QiaSeq xHyb Mycobacterium Tuberculosis Panel
• 5.11 WGS Uncovers Genetic causes of cerebral palsy
• 5.12 Rapid WGS Use recommended for Intensive Care
• 5.13 Quest and Ultima Genomics to Develop Tests
• 5.14 WHO launches WGS Guide
• 5.15 Myriad Genetics to Study MRD Testing
• 5.16 Adela Developing Epigenetic Multi-Cancer Detection
• 5.17 Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
• 5.18 Bionano Laboratories Announces New Prenatal Whole Genome Tests
• 5.19 Myriad Genetics Plans Product Launches
• 5.20 Genomics England, Aims to Sequence 100K Newborns
• 5.21 Juno Diagnostics NIPT With At-Home Sample Collection
• 5.22 Cardio Diagnostics Launches Genetic Cardio Risk Test
• 5.23 Universal Genetic Testing in Breast Cancer Further Supported
• 5.24 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
• 5.25 MyOme Lands Investment for WGS
• 5.26 GenomSys Gains CE Mark for New Genomic Analysis Software
• 5.27 WGS Finds Lung Cancers Fall Into Molecular Subtypes
• 5.28 Testing Distinguishes Benign Tumors From Precancerous Condition
• 5.29 Plan to Sequence All Newborns in UK
• 5.30 Clear Labs Raises $60M for Nanopore Sequencing
• 5.31 Variantyx Expands Into Prenatal, Cancer Testing
• 5.32 Whole-Genome Sequencing Aids Diagnosis in Stockholm
• 5.33 Variantyx Raises $20M
• 5.34 Nonacus WGS Service for SARS-CoV-2 Laboratories
• 5.35 Center to Report Risk Scores in Clinical WGS
• 5.36 Stanford Launches WGS for Cardiovascular Testing
• 5.37 Illumina and NY Healthcare Partner on Clinical WGS
• 5.38 Increased Adoption of WGS Needs Acceptance by Payors, Providers
• 5.39 Veritas Intercontinental Completes Euro 5M Series B Financing Round
• 5.40 M2GEN and Discovery Life Sciences in Bioinformatics Agreement
• 5.41 Genomics England Adopts Quantum ActiveScale Object Storage
• 5.42 GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
• 5.43 NHS Wales Introduces WGS for Critically Ill Newborns
• 5.44 Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
• 5.45 C2i Genomics to Launch Trials for MRD Detection Tech
• 5.46 Roche Acquires Sequencing Company Stratos Genomics
• 5.47 UK COVID-19 Sequencing Consortium Launches
• 5.48 Invitae Acquires Three Companies: YouScript, Genelex, Diploid
• 5.49 Experience From Centralized Genomic Medicine Lab
• 5.50 MGI to Enable $100 Human Genome
• 5.51 Nebula Genomics offers $299 WGS
• 5.52 Team to Study Campylobacter Omics
• 5.53 Veritas Genetics Restarts US Business
• 5.54 NEOGEN, Gencove partner to advance animal genomics

6 Profiles of Key Companies

• 6.1 10x Genomics, Inc.
• 6.2 1928 Diagnostics
• 6.3 23andME Inc.
• 6.4 Abbott Laboratories
• 6.5 AccuraGen Inc.
• 6.6 Adaptive Biotechnologies
• 6.7 Admera Health, LLC
• 6.8 Agilent/Dako
• 6.9 Akonni Biosystems
• 6.10 Amoy Diagnostics Co., Ltd.
• 6.11 Ancestry.com LLC
• 6.12 Anchor Dx
• 6.13 ARUP Laboratories
• 6.14 BaseClear
• 6.15 Baylor Miraca Genetics Laboratories
• 6.16 Beckman Coulter Diagnostics
• 6.17 Becton, Dickinson and Company
• 6.18 BGI Genomics Co. Ltd
• 6.19 Bioarray Genetics
• 6.20 Biocept, Inc.
• 6.21 Biodesix Inc.
• 6.22 BioFluidica
• 6.23 BioGenex
• 6.24 Biolidics Ltd
• 6.25 bioMerieux Diagnostics
• 6.26 Bioneer Corporation
• 6.27 Bio-Rad Laboratories, Inc
• 6.28 Bio-Techne
• 6.29 C2i Genomics
• 6.30 Caris Molecular Diagnostics
• 6.31 CellMax Life
• 6.32 Centogene
• 6.33 Circulogene
• 6.34 Clear Labs
• 6.35 Clinical Genomics
• 6.36 Complete Genomics, Inc. - A BGI Company
• 6.37 CosmosID
• 6.38 Dante Labs
• 6.39 Datar Cancer Genetics Limited
• 6.40 Day Zero Diagnostics.
• 6.41 Diasorin S.p.A.
• 6.42 Element Biosciences
• 6.43 Element Biosciences
• 6.44 Epic Sciences
• 6.45 Epigenomics AG
• 6.46 Eurofins Scientific
• 6.47 Excellerate Bioscience
• 6.48 Fabric Genomics
• 6.49 Freenome
• 6.50 FUJIFILM Wako Diagnostics
• 6.51 Fulgent Genetics
• 6.52 GE Global Research
• 6.53 Gencove
• 6.54 Genedrive
• 6.55 GeneDx Holdings
• 6.56 GeneFirst Ltd.
• 6.57 Genetron Holdings
• 6.58 Genewiz
• 6.59 Genomics England
• 6.60 Genomics Personalized Health (GPH)
• 6.61 GenomOncology
• 6.62 Genzyme Corporation
• 6.63 Grifols
• 6.64 Guardant Health
• 6.65 Guardiome
• 6.66 HeiScreen
• 6.67 Helix
• 6.68 Helix OpCo
• 6.69 Helomics
• 6.70 Hologic
• 6.71 HTG Molecular Diagnostics
• 6.72 Human Longevity, Inc.
• 6.73 iCellate
• 6.74 Illumina
• 6.75 Incell Dx
• 6.76 Inivata
• 6.77 Invitae Corporation
• 6.78 Invivoscribe
• 6.79 Karius
• 6.80 Lunglife AI Inc
• 6.81 Macrogen
• 6.82 MDNA Life SCIENCES, Inc.
• 6.83 MDx Health
• 6.84 Medgenome
• 6.85 Meridian Bioscience
• 6.86 Mesa Biotech (Thermo Fisher)
• 6.87 Mesa Laboratories, Inc.
• 6.88 miR Scientific
• 6.89 MNG Labs
• 6.90 NantHealth, Inc.
• 6.91 Natera
• 6.92 Nebula Genomics
• 6.93 NeoGenomics
• 6.94 New England Biolabs, Inc.
• 6.95 Novogene Bioinformatics Technology Co., Ltd.
• 6.96 Omega Bioservices
• 6.97 Oncocyte
• 6.98 OncoDNA
• 6.99 OpGen
• 6.100 ORIG3N, Inc.
• 6.101 Origene Technologies
• 6.102 Oxford Nanopore Technologies
• 6.103 Pacific Biosciences
• 6.104 Panagene
• 6.105 Pathogenomix
• 6.106 PathoQuest S.A.
• 6.107 Personal Genome Diagnostics
• 6.108 Personalis
• 6.109 Precipio
• 6.110 PrecisionMed
• 6.111 Promega
• 6.112 Protagen Diagnostics
• 6.113 Qiagen
• 6.114 QuantuMDx
• 6.115 Regeneron Pharmaceuticals
• 6.116 Revvity
• 6.117 Roche Molecular Diagnostics
• 6.118 Roswell Biotechnologies
• 6.119 Seegene
• 6.120 Sequencing.com
• 6.121 Siemens Healthineers
• 6.122 simfo GmbH
• 6.123 Singlera Genomics Inc.
• 6.124 Singular Genomics
• 6.125 SkylineDx
• 6.126 Standard BioTools
• 6.127 Sure Genomics, Inc.
• 6.128 Sysmex
• 6.129 Sysmex Inostics
• 6.130 Tempus Labs, Inc.
• 6.131 Thermo Fisher Scientific Inc.
• 6.132 Ultima Genomics
• 6.133 Ultima Genomics
• 6.134 Variantyx
• 6.135 Volition
• 6.136 Vyant Bio
• 6.137 Zymo Research Corp

7 The Global Market for Whole Genome Sequencing

• 7.1 Global Market Overview by Country
  • 7.1.1 Table - Global Market by Country
  • 7.1.2 Chart - Global Market by Country
• 7.2 Global Market by Application - Overview
  • 7.2.1 Table - Global Market by Application
  • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
  • 7.2.3 Chart - Global Market by Application - Base Year
  • 7.2.4 Chart - Global Market by Application - Final Year
  • 7.2.5 Chart - Global Market by Application - Share by Year
  • 7.2.6 Chart - Global Market by Application - Segment Growth
• 7.3 Global Market by Organism - Overview
  • 7.3.1 Table - Global Market by Organism
  • 7.3.2 Chart - Global Market by Organism - Base/Final Year Comparison
  • 7.3.3 Chart - Global Market by Organism - Base Year
  • 7.3.4 Chart - Global Market by Organism - Final Year
  • 7.3.5 Chart - Global Market by Organism - Share by Year
  • 7.3.6 Chart - Global Market by Organism - Segment Growth
• 7.4 Global Market by Product - Overview
  • 7.4.1 Table - Global Market by Product
  • 7.4.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 7.4.3 Chart - Global Market by Product - Base Year
  • 7.4.4 Chart - Global Market by Product - Final Year
  • 7.4.5 Chart - Global Market by Product - Share by Year
  • 7.4.6 Chart - Global Market by Product - Segment Growth
• 7.5 Global Market by Whole/Exome - Overview
  • 7.5.1 Table - Global Market by Whole/Exome
  • 7.5.2 Chart - Global Market by Whole/Exome - Base/Final Year Comparison
  • 7.5.3 Chart - Global Market by Whole/Exome - Base Year
  • 7.5.4 Chart - Global Market by Whole/Exome - Final Year
  • 7.5.5 Chart - Global Market by Whole/Exome - Share by Year
  • 7.5.6 Chart - Global Market by Whole/Exome - Segment Growth

8 Global Whole Genome Sequencing Markets - by Application

• 8.1 Research
  • 8.1.1 Table Research - by Country
  • 8.1.2 Chart - Research Growth
• 8.2 Clinical Human
  • 8.2.1 Table Clinical Human - by Country
  • 8.2.2 Chart - Clinical Human Growth
• 8.3 Clinical Human Rapid
  • 8.3.1 Table Clinical Human Rapid - by Country
  • 8.3.2 Chart - Clinical Human Rapid Growth
• 8.4 Clinical Tumor
  • 8.4.1 Table Clinical Tumor - by Country
  • 8.4.2 Chart - Clinical Tumor Growth
• 8.5 Clinical Pathogen
  • 8.5.1 Table Clinical Pathogen - by Country
  • 8.5.2 Chart - Clinical Pathogen Growth
• 8.6 Direct to Consumer
  • 8.6.1 Table Direct to Consumer - by Country
  • 8.6.2 Chart - Direct to Consumer Growth
• 8.7 Agriculture/Other
  • 8.7.1 Table Agriculture/Other - by Country
  • 8.7.2 Chart - Agriculture/Other Growth

9 Global Whole Genome Sequencing Markets - by Organism

• 9.1 Human
  • 9.1.1 Table Human - by Country
  • 9.1.2 Chart - Human Growth
• 9.2 Pathogen
  • 9.2.1 Table Pathogen - by Country
  • 9.2.2 Chart - Pathogen Growth
• 9.3 Other Organism
  • 9.3.1 Table Other Organism - by Country
  • 9.3.2 Chart - Other Organism Growth

10 Global Whole Genome Sequencing Markets - by Product

• 10.1 Instruments
  • 10.1.1 Table Instruments - by Country
  • 10.1.2 Chart - Instruments Growth
• 10.2 Reagents
  • 10.2.1 Table Reagents - by Country
  • 10.2.2 Chart - Reagent Growth
• 10.3 Analysis
  • 10.3.1 Table Analysis - by Country
  • 10.3.2 Chart - Analysis Growth
• 10.4 Software & Other
  • 10.4.1 Table Software & Other - by Country
  • 10.4.2 Chart - Software & Other Growth

11 Global Whole Genome Sequencing Markets - by Whole/Exome

• 11.1 Whole Genome
  • 11.1.1 Table Whole Genome - by Country
  • 11.1.2 Chart - Whole Genome Growth
• 11.2 Exome Only
  • 11.2.1 Table Exome Only - by Country
  • 11.2.2 Chart - Exome Only Growth
• 11.3 Other/Mix
  • 11.3.1 Table Other/Mix - by Country
  • 11.3.2 Chart - Other/Mix Growth

12 Vision of the Future of Whole Genome Sequencing

13 Appendices

• 13.1 United States Medicare System: Laboratory Fees Schedule
• 13.2 The Most Used IVD Assays
• 13.3 The Highest Grossing Assays
• 13.4 The Whole Genome Sequence of SARS-CoV-2

Table of Tables

• Table 1 The Base Pairs
• Table 2 Most Common Traditional Genetic Disorders
• Table 3 List of GLOBAL SEQUENCING LOCATIONS
• Table 4 Market Players by Type
• Table 5 The Different Markets for Whole Genome Sequencing
• Table 6 DTC Sub Segments
• Table 7 Roles of WGS in AgriBio
• Table 8 The Factors Driving Growth
• Table 9 Factors Limiting Growth
• Table 10 - Listing of Current NGS Instrument Specifications
• Table 11 Six New Sequencing Technologies
• Table 12 - Global Market by Region
• Table 13 Global Market by Application
• Table 14 Global Market by Organism
• Table 15 Global Market by Product
• Table 16 Global Market by Whole/Exome
• Table 17 Research by Country
• Table 18 Clinical Human by Country
• Table 19 Clinical Human Rapid by Country
• Table 20 Clinical Tumor by Country
• Table 21 Clinical Pathogen by Country
• Table 22 Direct to Consumer by Country
• Table 23 Agriculture/Other by Country
• Table 24 Human by Country
• Table 25 Pathogen by Country
• Table 26 Other Organism by Country
• Table 27 Instruments by Country
• Table 28 Reagents by Country
• Table 29 Analysis by Country
• Table 30 Software & Other by Country
• Table 31 Whole Genome by Country
• Table 32 Exome Only by Country
• Table 33 Other/Mix by Country
• Table 34 Clinical Lab Fee Schedule
• Table 35 The Most Common Assays
• Table 36 Largest Revenue Assays

Table of Figures

• Figure 1 Global Healthcare Spending
• Figure 2 The Lab Test Pie
• Figure 3 Size of Genome for Various Species
• Figure 4 - Cost To Sequence a Human Genome
• Figure 5 Base Year Country Market Share Chart
• Figure 6 Global Market by Application - Base vs. Final Year
• Figure 7 Global Market by Application Base Year
• Figure 8 Global Market by Application Final Year
• Figure 9 Application Type Share by Year
• Figure 10 by Application Segment Growth
• Figure 11 by Organism - Base vs. Final Year
• Figure 12 by Organism Market Base Year
• Figure 13 by Organism Market Final Year
• Figure 14 by Organism Share by Year
• Figure 15 by Organism Segment Growth
• Figure 16 by Product - Base vs. Final Year
• Figure 17 by Product Market Base Year
• Figure 18 by Product Market Final Year
• Figure 19 by Product Share by Year
• Figure 20 by Product Segment Growth
• Figure 21 by Whole/Exome - Base vs. Final Year
• Figure 22 by Whole/Exome Market Base Year
• Figure 23 by Whole/Exome Market Final Year
• Figure 24 by Whole/Exome Share by Year
• Figure 25 by Whole/Exome Segment Growth
• Figure 26 Research Growth
• Figure 27 Clinical Human Growth
• Figure 28 Clinical Human Growth
• Figure 29 Clinical Tumor Growth
• Figure 30 Clinical Pathogen Growth
• Figure 31 Direct to Consumer Growth
• Figure 32 Agriculture/Other Growth
• Figure 33 Human Growth
• Figure 34 Pathogen Growth
• Figure 35 Other Organism Growth
• Figure 36 Instruments Growth
• Figure 37 Reagent Growth
• Figure 38 Analysis Growth
• Figure 39 Software & Other Growth
• Figure 40 Whole Genome Growth
• Figure 41 Exome Only Growth
• Figure 42 Other/Mix Growth